ICICI Prudential Asset Management Co Ltd Sells 12,241 Shares of Biogen Inc. $BIIB

ICICI Prudential Asset Management Co Ltd cut its holdings in shares of Biogen Inc. (NASDAQ:BIIB) by 56.4% during the fourth quarter, Holdings Channel reports. The fund owned 9,462 shares of the biotechnology company’s stock after selling 12,241 shares during the period. ICICI Prudential Asset Management Co Ltd’s holdings in Biogen were worth $1,665,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of BIIB. Empowered Funds LLC grew its position in Biogen by 64.9% during the 1st quarter. Empowered Funds LLC now owns 7,054 shares of the biotechnology company’s stock worth $965,000 after acquiring an additional 2,777 shares during the last quarter. Focus Partners Wealth grew its position in Biogen by 172.2% during the 1st quarter. Focus Partners Wealth now owns 10,173 shares of the biotechnology company’s stock worth $1,392,000 after acquiring an additional 6,436 shares during the last quarter. Sivia Capital Partners LLC bought a new stake in Biogen during the 2nd quarter worth approximately $216,000. Cerity Partners LLC grew its position in Biogen by 15.3% during the 2nd quarter. Cerity Partners LLC now owns 46,552 shares of the biotechnology company’s stock worth $5,847,000 after acquiring an additional 6,184 shares during the last quarter. Finally, NewEdge Advisors LLC grew its position in Biogen by 13.4% during the 2nd quarter. NewEdge Advisors LLC now owns 2,673 shares of the biotechnology company’s stock worth $336,000 after acquiring an additional 316 shares during the last quarter. 87.93% of the stock is currently owned by institutional investors.

Biogen Stock Up 2.9%

NASDAQ:BIIB opened at $199.96 on Friday. Biogen Inc. has a 12-month low of $121.05 and a 12-month high of $205.97. The company has a quick ratio of 2.41, a current ratio of 3.06 and a debt-to-equity ratio of 0.34. The firm has a market capitalization of $29.52 billion, a P/E ratio of 21.45 and a beta of 0.20. The stock’s fifty day simple moving average is $188.40 and its 200-day simple moving average is $184.20.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.95 by $0.62. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The business had revenue of $2.48 billion for the quarter, compared to analyst estimates of $2.29 billion. During the same period last year, the company earned $3.02 EPS. The firm’s revenue was up 1.9% on a year-over-year basis. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Equities research analysts expect that Biogen Inc. will post 14.18 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on BIIB shares. Citigroup increased their price target on Biogen from $190.00 to $200.00 and gave the stock a “neutral” rating in a research report on Friday, May 1st. Guggenheim increased their price objective on Biogen from $246.00 to $260.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. Wedbush increased their price objective on Biogen from $191.00 to $196.00 and gave the company a “neutral” rating in a research report on Thursday, April 30th. JPMorgan Chase & Co. increased their price objective on Biogen from $175.00 to $185.00 and gave the company a “neutral” rating in a research report on Thursday, April 23rd. Finally, Argus upgraded Biogen to a “hold” rating in a research report on Thursday, April 9th. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $217.26.

Key Headlines Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: At Biogen’s 2026 annual meeting, shareholders backed the board, auditor, and pay-related proposals, signaling continued investor support for management and governance. Biogen Shareholders Back Board, Auditor and Pay Policies
• Positive Sentiment: Biogen has recently outperformed other biotech stocks, with commentary noting that analysts remain reasonably upbeat about its prospects. How Is Biogen’s Stock Performance Compared to Other Biotech Stocks?
• Neutral Sentiment: Denali Therapeutics highlighted that it halted joint work with Biogen on BIIB122 for Parkinson’s disease after Phase 2b results, which appears to be a program setback but is not necessarily a direct blow to Biogen’s broader business. What Makes Denali Therapeutics (DNLI) One of the Best AI Driven Biotech Names
• Negative Sentiment: Two shareholder-law firms, Schall and Pomerantz, announced investigations into possible false or misleading statements by Biogen, increasing the risk of litigation headlines and potential investor uncertainty. BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. – BIIB
• Negative Sentiment: MarketWatch also noted that Biogen underperformed peers on Wednesday, suggesting the stock has been lagging some competitors despite its recent longer-term strength. Biogen Inc. stock underperforms Wednesday when compared to competitors

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.